Article Text


Adrenaline autoinjectors and schoolchildren: a community based study
  1. T P Blyth,
  2. R Sundrum
  1. Hounslow & Spelthorne Community and Mental Health NHS Trust, The Thelma Golding Centre, 92 Bath Road, Hounslow, Middlesex TW3 3EL, UK
  1. Correspondence to:
    Dr R Sundrum, Hounslow & Spelthorne Community and Mental Health NHS Trust, The Thelma Golding Centre, 92 Bath Road, Hounslow, Middlesex TW3 3EL, UK;


Sixty schoolchildren prescribed adrenaline autoinjectors were identified by surveying schools in Hounslow, London; the 25 families who consented were interviewed. There was inconsistency in prescription and use of autoinjectors with poor training, absence of written instructions, and lack of follow up. It is recommended that national guidelines should be developed.

  • allergy
  • adrenaline
  • management
  • community

Statistics from

Use of adrenaline autoinjectors is emphasised in the management of anaphylaxis. There is debate about whether too many autoinjectors are being prescribed,1 and whether they are used correctly.2–4

Previous studies have focused on children attending tertiary allergy clinics. Our aim was to obtain information about all schoolchildren using adrenaline autoinjectors.


Questionnaires were sent to all schools in the London Borough of Hounslow. A representative of each school was asked to indicate the number of children with an adrenaline autoinjector and to give these children an information sheet requesting consent for interview.

We interviewed parents regarding the reasons for adrenaline prescription, indications for use, number and location of adrenaline autoinjectors, follow up arrangements, and the effect the prescription had had on the family. We also observed a demonstration of administration technique.

Approval for the study was obtained from the Hounslow Research Ethics Committee.


Fifty six of the 86 schools in Hounslow returned the questionnaire. The other 30 were contacted by telephone. We identified 60 pupils with adrenaline autoinjectors in the school population of 36 000. Individual schools reported between zero and four pupils. Consent for interview was obtained from 25 families. No information was available about non-responders.

Of the 25 children interviewed, 13 were boys. Median age was 9 years (range 4–17). The median age at which the adrenaline autoinjector had been prescribed was 6 years (range 1–12). The median duration of prescription was 3 years (range 1 month to 5 years).

Sixteen children had been prescribed adrenaline for allergy to peanut (64%) and five children (20%) for allergy to tree nut. Of the children with nut allergy, 10 reported that their most severe reaction had been facial swelling, eight reported respiratory difficulty, two reported vomiting, and one had no symptoms but a positive radioallergosorbent test (RAST). Eleven of these children had coexisting asthma.

Half the children were under the care of a paediatrician at a district general hospital, a quarter were under the care of their general practitioner, and a quarter attended a tertiary allergy clinic. As table 1 shows, allergy testing and follow up were more frequent in children attending hospital clinics. Children seen in allergy clinics were prescribed more autoinjectors. Although the majority of families received allergy training, very few had a written management plan.

Table 1

Management of children with adrenaline autoinjectors

Three children had been prescribed an incorrect dose, in all cases because they had remained on a low dose autoinjector rather than changing to full strength when they reached 30 kg, as recommended by the manufacturer.

Table 2 summarises the knowledge of children and carers about when and how to use their adrenaline autoinjectors. Only 18 mentioned respiratory difficulty as an indication, and only six were able to demonstrate correctly on a dummy how to use their autoinjector (similar to previous studies3). The main areas of difficulty were not removing the cap (n = 8) and pressing on the tip to inject while holding the autoinjector against the thigh (n = 10).

Table 2

Knowledge regarding anaphylaxis

Ten children had experienced further allergic reactions, of which two children received adrenaline. The first had facial swelling at a party but did not have his autoinjector. His mother brought it from home and gave it to him 30 minutes after the onset of symptoms. The second had facial swelling and faintness while on holiday. The family had not brought his autoinjector, so took him to the local hospital where he was given adrenaline. The three children with wheeze used inhaled bronchodilators rather than adrenaline. The other reactions (facial swelling or rash) were controlled using oral antihistamines.

Only two schools requested further training for teachers. This may be a result of the presence of a programme of training for schoolteachers developed by the school nursing team in Hounslow.


This study was designed to identify whether there are areas of difficulty in the use of adrenaline autoinjectors prescribed to schoolchildren. For ethical reasons we did not contact families directly, but relied on them agreeing to participate on the basis of information passed to them by schools. The characteristics of the families who agreed to take part in the study are likely to be different from those who did not. Therefore we can make no conclusions about non-respondents. It is possible that they are less motivated than respondents, and therefore even less well informed. Alternatively, families who felt confident about using autoinjectors may not have responded.

The inconsistency we found in advice given to parents means that schools may have different instructions for different pupils. Widespread use of written instructions would help to decrease confusion. Ewan and Clark claim that it also prevents severe or life threatening reactions.5

The lack of follow up noted has two main consequences. Firstly, children who may have outgrown their allergies (recent studies have shown that peanut allergy may resolve with time6), or who were prescribed adrenaline autoinjectors for reasons that no longer warrant one are not being identified. Secondly, families are not able to have refresher training.

In summary, our study has shown that there are several areas of difficulty surrounding the use of adrenaline autoinjectors in the community. The main problems are a lack of consistency in management, problems with training, and poor follow up. We recommend development of evidence based national guidelines.


View Abstract

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.